Covishield side effects: AstraZeneca expresses 'sympathy' for those who lost loved ones

Following AstraZeneca's acknowledgment of a rare side effect associated with its COVID-19 vaccine, known as Covishield in India, the UK pharmaceutical giant extended sympathy to those impacted. Reaffirming its dedication to patient safety amidst concerns about potential rare side effects, AstraZeneca emphasised the vaccine's overall safety profile. The company underscored the stringent standards of regulatory authorities to ensure the safe use of medicines, including vaccines. AstraZeneca highlighted the extensive clinical trial data and real-world evidence consistently supporting the safety and efficacy of the vaccine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F0dLfzQ
via IFTTT

Read More

Lilavati trustee alleges Rs 500 crore scam by kin

Prashant Mehta, a trustee of Lilavati Hospital & Research Centre in Mumbai, accused former trustees of misappropriating ₹500 crore in trust funds. Allegations include payments for private disputes, bogus donations, and advances to real estate firms. Prashant named his late uncle Vijay Mehta, cousin Niket Mehta, and aunt Sushila Mehta in the accusations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/js6y31F
via IFTTT

Read More

Covishield row: 'Very rare chances…', ex-AIIMS doctor explains severe side-effects of covid vaccine

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SIqJXtn
via IFTTT

Read More

Covishield Case: Bereaved parents to take Serum Institute of India to Court following AstraZeneca's rare side effect admission

The parents of a woman allegedly deceased after receiving the Covishield vaccine plan to file a case against the Serum Institute of India (SII). This decision follows AstraZeneca's acknowledgment in court that their Covid shot can cause a rare side effect, providing hope for the parents in seeking justice. AstraZeneca faces a class-action lawsuit over allegations that its vaccine, developed with the University of Oxford, led to deaths and serious injuries, including thrombosis with thrombocytopenia syndrome (TTS), characterized by blood clots and low platelet count.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/B1uRIk9
via IFTTT

Read More

Covishield Side Effects: What's TTS syndrome, symptoms, and danger signs you shouldn't ignore

Covishield TTS: AstraZeneca has acknowledged the potential TTS side effects from its COVID-19 vaccine Covishield, used widely in India. TTS, Thrombosis with Thrombocytopenia Syndrome, is rare but serious, marked by blood clots and low platelet levels. Symptoms include headaches, blurred vision, and chest pain. Dr. Jayadevan emphasizes awareness, stressing early treatment for effective management. AstraZeneca's admission follows reports of TTS linked to adenovirus vector vaccines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0iDEpzW
via IFTTT

Read More

Indian pharmaceutical industry set for major transformation: Dilip Shanghvi

At an annual meeting of the USA-India Chamber of Commerce in Boston, Shanghvi told a gathering of leading multinational drug makers about the "clear positive improvements" that are taking place in India. Sun Pharma itself has built a pipeline of over 10 specialty and innovative drugs in the US. It's done this through acquisitions of late-stage drugs in clinical trials and building commercial teams around them. For Indian companies that have grown by making copies of innovative drugs, gaining presence in innovative drugs is considered tough as this segment is dominated by giant corporations such as Pfizer, Novartis, Roche, Eli Lilly and Bristol Myers Squibb.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cUHOp9a
via IFTTT

Read More

Drug firms told to set up system for 'prompt' recalls

India enforced 'Schedule M' for drug manufacturers, emphasizing quality, recall systems. Companies must comply with strict rules on hygiene, audits, and reporting defects to DCGI for improved drug quality and safety measures. For seamless implementation of the new rules, the health ministry has been conducting workshops and giving presentations to pharma companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F0SB3ri
via IFTTT

Read More

AstraZeneca acknowledges covid vaccine can lead to rare side effect TSS in court; Here's what we know

AstraZeneca, in collaboration with the University of Oxford, admits its Covid-19 vaccine can cause a rare side effect, Thrombosis with Thrombocytopenia Syndrome (TTS). The admission comes amidst a lawsuit alleging severe harm and deaths caused by the vaccine. Kate, wife of a victim, demands an apology and fair compensation after a three-year struggle. The lawsuit, involving fifty-one cases, seeks around £100 million in compensation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IB2ihpV
via IFTTT

Read More

Manipal Hospitals to acquire Kolkata's Medica Synergie

Manipal Hospitals has acquired an 87% stake in Kolkata-based Medica Synergie, a subsidiary of Singapore's Temasek Holdings. The deal, valued at Rs1200 crore, is part of Manipal Hospitals' strategy to expand its presence in Eastern India. The acquisition comes after Sheares Health, the healthcare platform owned by Singapore's Temasek Holdings, acquired an additional 41% stake from existing investors and the promoter family for Rs16,500 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W8oeRSZ
via IFTTT

Read More

Glenmark Pharma gets USFDA nod for generic anti-inflammatory drug

Glenmark Pharmaceuticals received USFDA approval for generic Acetaminophen and Ibuprofen tablets. The product, a version of Advil Dual Action, will be distributed by Glenmark Therapeutics Inc, USA. Advil Dual Action achieved annual sales of around USD 84.1 million. Glenmark has 195 products authorized for distribution and 52 ANDAs pending approval.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fp48DOa
via IFTTT

Read More

Dr Reddy’s, Sun, Cipla and Biocon look to recreate Ozempic magic in India

Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife for my appearance,” says Rajput. The drugs — Wegovy and Ozempic — which have the same ingredient, semaglutide, are all the rage ever since entrepreneur Elon Musk tweeted about it.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QpuKqgU
via IFTTT

Read More

‘Obese people should opt for a structured programme of diet, exercise & medication’

"Nothing comes without a downside. These molecules do produce significant nausea and vomiting in some people — to the extent that they have to discontinue the medication. Some may develop diarrhoea, some may have severe constipation. Others may not like the way they lose weight—they may feel very shrunken or their face may seem very thinned out. That’s another sort of downside," says Dr Ambrish Mithal, chairman, endocrinology & diabetes, Max Healthcare, Delhi.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/or37hP8
via IFTTT

Read More

India becoming attractive for clinical trials, says pharma industry leaders

Over the past decade, India has seen significant improvements in its clinical trial landscape, with a 15-18% growth in phase two and three trials. This growth is attributed to 10 modifications to the Drugs and Cosmetics Act since 2013, aimed at simplifying the process. Despite these advancements, conducting trials in India can still be challenging. Experts note that India's modernizing private hospital networks and improved infrastructure make it an attractive location for trials, with potential for further growth and collaboration in the future.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nJkTo3U
via IFTTT

Read More

Pharma, financial services lead in female KMP representation

While female KMPs in the financial services sector were all professional leaders, in pharma, they were promoters, according to data from FY23 collated for ET by executive search firm EMA Partners India.However, Indian companies continue to struggle to have a better gender balance when it comes to KMPs. According to the Companies Act, KMPs are the CEOs or managing directors, chief financial officers, company secretaries and wholetime directors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y6PQ1in
via IFTTT

Read More

PE Advent International queues up for a stake in Apollo 24/7

Apollo 24/7 is part of Apollo HealthCo, a subsidiary of Apollo Hospitals. HealthCo also houses the pharmacy distribution business and a 25.5% interest in Apollo Pharmacy. It accounts for about 40% of Apollo Hospitals’ revenue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Vy62hgj
via IFTTT

Read More

Pharma leads in assigning key managerial roles to women

While female KMPs in the financial services sector were all professional leaders, in pharma, they were promoters, according to data from FY23 collated for ET by executive search firm EMA Partners India.However, Indian companies continue to struggle to have a better gender balance when it comes to KMPs. According to the Companies Act, KMPs are the CEOs or managing directors, chief financial officers, company secretaries and wholetime directors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bYsD2tC
via IFTTT

Read More

Medical devices companies to soon have 'unique' pricing model

At present there is no separate pricing framework followed for medical devices. The government has been using the same framework which was created for drugs in case they want to regulate the price of any medical device. Earlier, it had regulated the prices of stents and knee implants under the Drug Price Control Order.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KItye9C
via IFTTT

Read More

Sugar, you shrunk the kids: Bouquet of diseases nestled within your child's nutritional drinks

Have you been a fan of "nutritional" drinks since childhood? Chances are, the milk you consumed was laden with about 50% sugar. This habit may have continued into adulthood, contributing to India's reputation as the "diabetes capital of the world." Recent controversies surrounding Nestle's Cerelac have exposed the issue of added sugar in products for infants. As concerns grow over high sugar content in supposedly nutritious drinks, it is crucial for consumers to be aware of their sugar intake, particularly for children.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nz0WNMl
via IFTTT

Read More

Nestle, Dr Reddy's to form JV to market nutraceutical brands in India

Nestle India and Dr. Reddy’s form a joint venture to introduce new nutraceutical brands in India. The collaboration merges health solutions and commercial capabilities to enhance consumer access and affordability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p0rLGDf
via IFTTT

Read More

Optimizing gut health: Avoid these foods for better digestive wellness

Protect your gut health by avoiding certain foods. Processed foods, artificial sweeteners, high-sugar items, fried foods, alcohol, and processed meats can harm gut bacteria and cause inflammation, leading to digestive issues. Opt for whole, nutrient-rich foods for better digestive wellness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wrIT41c
via IFTTT

Read More

Govt expands committee for drug and medical device pricing reforms, includes more industry representation

The government has expanded a committee to include more industry representation for reviewing drug and medical device pricing reforms. This move aims to ensure better availability of medicines and devices, while also providing incentives for industry growth and export sustainability. The committee will engage with industry experts and associations to evaluate pricing and availability issues. Ultimately, the government will make the final decisions, with the committee focusing on balancing pricing and availability of essential medicines and designing a price moderation framework for medical devices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3qXwgao
via IFTTT

Read More

Revamped health schemes to focus on kids' nutrition

"The idea is to come up with a comprehensive physical and mental development programme for schoolchildren, with a focus on nutrition to minimise cases of anaemia and to strengthen their mental health to reduce increasing incidence of anxiety, depression and suicides," said a senior government official.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rVawApL
via IFTTT

Read More

Dr Reddy's recalls six lots of drug in US due to subpotency

Dr Reddy's Laboratories on Tuesday said it is voluntarily recalling from the US market six lots of medication, indicated to reduce blood phenylalanine (Phe) levels, on account of being subpotent. The company is recalling affected lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level due to powder discolouration in some packets leading to decreased potency, the Hyderabad-based drug maker said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cjns2tQ
via IFTTT

Read More

Panel to finalise list of over-the-counter drugs for sale at general stores

A three-member committee of gynecologists has been formed to finalize a list of over-the-counter (OTC) drugs that will be available in regular stores without the need for a prescription. The committee, chaired by Directorate General of Health Services Atul Goel, aims to complete the list within two weeks. This move is part of India's new OTC policy for drugs, which seeks to reduce treatment costs and promote self-care while ensuring safety. The list will be based on factors such as safety, availability, and non-habit-forming nature of the drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y9ehkxp
via IFTTT

Read More

Zydus Lifesciences launches generic drug for overactive bladder in US market

Zydus is among the first suppliers to launch the generic version of Mirabegron extended-release tablets (USP 25 mg) in the US market. The company is also preparing to launch the 50 mg tablets in the market. Mirabegron is indicated for the treatment of Overactive Bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3uByqxE
via IFTTT

Read More

USFDA pulls up Natco Pharma for manufacturing lapses at Telangana plant

Natco Pharma's Telangana plant violated cleanliness and sterilisation standards at Kothur Village facility per USFDA. The warning letter mentioned cross-contamination, inadequate cleaning procedures, and the need for comprehensive investigations and corrective actions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g7FPTMO
via IFTTT

Read More

Healthcare needs tailored financing, knowledge and partnerships: World Bank President Ajay Banga

Healthcare needs tailored financing, knowledge and partnerships, says World Bank President Ajay Banga. He said, during and after COVID, financing for healthcare has increased but to make healthcare affordable and bring it to the reach of all, it needs knowledge and partnerships along with financing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zlqHY80
via IFTTT

Read More

Middle East crisis escalation may hurt pharma exports

While exports have not been affected so far, the next few days are crucial because, if there is serious escalation in the conflict, it could impact the whole Middle East and North Africa (MENA) region. Many Indian pharma companies have a significant presence in the region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aXf93DV
via IFTTT

Read More

CDCSO issues distribution guidelines for pharma products in market to curb substandard medicines

The Central Drugs Standard Control Organisation (CDSCO) has released draft guidelines on good distribution practices to prevent the introduction of spurious, adulterated, and sub-standard pharmaceutical products in the market. The guidelines are in line with the WHO Technical Report Series on good storage and distribution practices for such products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ErVWpAG
via IFTTT

Read More

Govt mulls allowing sale of common medicines in general stores

India's committee, under Atul Goel's leadership, is pioneering the development of guidelines for over-the-counter medicines to improve accessibility. This initiative marks a significant step towards streamlining non-prescription drug regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mnvWiqE
via IFTTT

Read More

Complaint filed against Natco Pharma in US by Fresenius Kabi

Natco Pharma faces a legal complaint from Fresenius Kabi in the US District Court regarding the marketing of Diazepam injection prefilled syringe. Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH filed the complaint against Natco Pharma USA LLC (formerly Dash Pharmaceuticals LLC).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tzlXKS7
via IFTTT

Read More

HCG founder floats $20 million healthcare and life sciences fund

BS Ajaikumar launched the $20 million Inviga Healthcare Fund to support Indian early-stage healthcare companies, addressing funding and operational challenges. The fund recently invested $2 million in Mynvax for novel vaccines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gEVcLkY
via IFTTT

Read More

HC upholds its earlier order on asthma drug Indamet against Glenmark Pharma

Sun Pharma Laboratories, a wholly-owned subsidiary of Sun Pharmaceutical Industries, and Glenmark are contesting over their right to use drug names “Istamet” and “Indamet”, respectively, which Sun Pharma finds to be deceptively similar and confusing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E5wHpdq
via IFTTT

Read More

Jubilant gets VAI classification from USFDA for Roorkee unit

As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/13ZIekR
via IFTTT

Read More

IIT Kanpur joins hands with Blockchain for Impact to accelerate healthcare innovation

IIT Kanpur partners with BFI under BFI-Biome Virtual Network Program to boost healthcare startups. $150,000 pledged for SIIC healthcare innovations. Emphasis on entrepreneurial initiatives, biomedical research, and impactful solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fEBy68i
via IFTTT

Read More

Calcutta HC passes interim order in Glocal case

UpHealth, a digital health company, acquired a 95% stake in Glocal in 2020. The dispute started after UpHealth claimed their right to two directors on the board of Glocal as per the share purchase agreement (SPA) in September 2022, which was defeated in an extraordinary general meeting (EGM).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6FdhQIa
via IFTTT

Read More

Delius Pharma registers 35% growth in sales, plans IPO in next 3 years

Delius Pharma registered a 35 percent rise in sales in FY23 to 24, with plans to set up multiple manufacturing units in India for finished formulation and API production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CTbszZO
via IFTTT

Read More

Do you consume protein supplements for health gains? Snapdeal's Kunal Bahl has a serious warning for you

A recent study exposes alarming findings about protein supplements, uncovering mislabeling, toxin contamination, and potential health risks. Led by researchers from Rajagiri Hospital in Kerala and a US-based tech entrepreneur, the study highlights the urgent need for stricter regulation in the supplement industry. Misleading labels and harmful toxins pose significant health hazards, prompting caution among consumers. The study's revelations underscore the importance of informed decision-making and regulatory reform to ensure product safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GnAxEqY
via IFTTT

Read More

Max Healthcare Institute to invest Rs 5,000 cr on doubling bed capacity in 4-5 years

Max Healthcare Institute Ltd plans to invest Rs 2,500 crore in Uttar Pradesh (UP) which includes setting up of a new 500 beds hospital on 5.6-acre parcel of land located at Shaheed Path and augmentation of capacity of the acquired facility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xsq1Qx7
via IFTTT

Read More

ChrysCap buys small stake in generics company La Renon for Rs 600 cr

Incorporated in 2007 by Pankaj Singh, La Renon is engaged in the manufacturing and marketing of branded generic formulations. ChrysCapital is close to acquiring a minority stake in La Renon Healthcare via secondary sale of shares, at a valuation of Rs 6,500 crore ($800 million), ET first reported on February 12.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ND62kWI
via IFTTT

Read More

Royal Phillips to expand its Healthcare Innovation Centre in Pune

Royal Philips expands its Pune Healthcare Innovation Centre, integrating R&D teams for various businesses. The new facility promotes sustainability and innovation, aiming to enhance patient and staff experiences while reducing the cost of care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mqN5Kpz
via IFTTT

Read More

India rubbishes Lancet report, says spending on healthcare is at all-time high

A recent Lancet report highlighted India's healthcare spending low at 1.2% of GDP, but government sources defended increased investments. The Health Ministry aims to reach 2.5% by 2025, with budgets rising significantly. Flagship initiatives like Ayushman Bharat aim to improve healthcare access, while efforts focus on reducing out-of-pocket expenses and expanding services nationwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BVck6hG
via IFTTT

Read More

India's pharma exports to US surge 15% in 11 months of FY24

The pace of exports has more than doubled from the 6.18% growth in the same period of FY23, according to estimates by Pharmaceutical Export Promotion Council (Pharmexcil).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/67G4pMS
via IFTTT

Read More

Glenmark recalls 6,528 bottles of blood pressure drug in US

As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mb9vjKz
via IFTTT

Read More

Neuberg Diagnostics plans to raise $100 million to fund acquisitions

Neuberg, which runs a pan-India diagnostic chain, has appointed O3 Capital as the investment banker and is currently in talks with potential investors, Velu said in an interview. The Chennai-based company plans to use the fresh capital to expand its radiology business through acquisitions, chairman GSK Velu said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W071zyA
via IFTTT

Read More

IPC issues alert on painkiller drug nimesulide over adverse reaction

Pharma standards body Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert over nimesulide, saying the pill can trigger rashes on the skin (fixed drug eruption). It asked consumers and healthcare professionals to closely monitor the use of the drug and report any adverse reaction to the National Coordination Centre-Pharmacovigilance Programme of India of the IPC.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mXd8vlE
via IFTTT

Read More

USFDA issues warning letter to Kilitch Healthcare for Navi-Mumbai plant

The US Food and Drug Administration (USFDA) has issued a warning letter to Kilitch Healthcare India for manufacturing lapses at its plant in Maharashtra. The letter highlights various violations of current good manufacturing practice (CGMP) regulations, including packing drugs in insanitary conditions and failing to establish proper procedures to prevent contamination. The USFDA observed that the facility was poorly cleaned and maintained, posing risks of contamination. Kilitch Healthcare has committed to suspending production of all drugs for the US market. The company must address the violations and provide a plan for corrective action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YPn9jiv
via IFTTT

Read More

Warburg buys majority stake in ophthalmic device company Appasamy

Warburg Pincus buys majority stake in Chennai's Appasamy Associates, a top Indian ophthalmic equipment and IOLs manufacturer. Appasamy CEO will continue to lead biz with support from promoter family

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YJiZFs9
via IFTTT

Read More

Dr Reddy's launches migraine management device in Europe

The launch marks the company's entry into digital therapeutics in Europe, the Hyderabad-based drug major said in a statement. Nerivio is approved by the US Food and Drug Administration (USFDA), and is CE-mark certified in Europe. Dr Reddy's launched Nerivio in India last year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yiCAtSx
via IFTTT

Read More

'Demand for Indian healthcare profs to double nationally, globally by 2030'

Global shortage and an ageing population have spurred the demand for Indian healthcare professionals who are highly respected in the international markets for their skills, NLB Services CEO Sachin Alug told PTI.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WnLvqjS
via IFTTT

Read More

Warburg Pincus acquires Chennai's Appasamy Associates

PSN Appasamy's Appasamy Associates, a key player in Indian ophthalmic market, focuses on affordable equipment and cataract surgeries. Warburg Pincus's investment reinforces growth potential in the sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/icYQS0o
via IFTTT

Read More

Relief for pharma companies as API prices see a sharp fall

India's pharmaceutical industry, which is dependent on China for APIs, intermediates and bulk drugs, had seen an exponential price increase during Covid times. The rise in API prices continued until early this year. However, things have started to change, people in the know told ET.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aTGh6FC
via IFTTT

Read More

How to use Niacinamide effectively in your skincare regimen

Here are six points detailing how to use niacinamide effectively in your skincare regimen.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CHSLVEK
via IFTTT

Read More

Natco Pharma gets warning letter from USFDA for Telangana plant

Natco Pharma, a pharmaceutical company, received a warning letter from the USFDA regarding its manufacturing plant in Telangana. This came after the FDA conducted an inspection of the company's facility in Kothur last October, issuing eight observations under Form 483.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LWQxeCP
via IFTTT

Read More

Strides Pharma gets USFDA nod for antidepressant medication

As per IMS, Fluoxetine tablets have a market size of USD 23.9 million. This approval further strengthens the company's presence in the Fluoxetine portfolio, complementing the existing approval of Fluoxetine capsules, which has a market size of USD106 million, the Bengaluru based firm said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hHZIsnJ
via IFTTT

Read More

Indian pharma market posts robust 9.5% growth in March

India's pharmaceutical market saw a 9.5% growth in March, reaching '16,158 crore in sales. The Moving Annual Total reached '197,976 crore with a 6.5% growth rate, with cardiology and anti-infectives among the top performers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7reSJpZ
via IFTTT

Read More

Lupin gets USFDA nod to market generic medication

Lupin has gained approval from the USFDA to market generic Valbenazine Capsules, used to treat tardive dyskinesia. This medication is equivalent to Neurocrine Biosciences, Inc's Ingrezza Capsules. Lupin is among the first applicants for this generic drug, entitling them to 180 days of shared exclusivity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/inV9PcK
via IFTTT

Read More

AstraZeneca, Daiichi Drug gets broad tumor approval in US

Enhertu, a collaboration between AstraZeneca and Daiichi Sankyo, gains FDA approval for treating HER2-positive solid tumors spread throughout the body, marking a breakthrough in cancer treatment. It's the first antibody drug conjugate with such wide clearance, offering new hope for patients with limited treatment options. AstraZeneca anticipates further growth opportunities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1kPBuEo
via IFTTT

Read More

Piramal Alternatives invests Rs 110 crore in Biodeal Pharmaceuticals

Piramal Alternatives invested Rs 110 crore in Noida-based Biodeal Pharmaceuticals through convertible instruments. The funding will enhance infrastructure, technology, and a nutraceuticals manufacturing facility. Biodeal is a key contract manufacturing player, specializing in nasal sprays and achieving PIC/S approval.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZCndIl6
via IFTTT

Read More

Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivot

Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in generic supply. The Bengaluru-based company secured UK approval for the first generic version of liraglutide injectible, positioning itself as a leader in this evolving market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BeadmRQ
via IFTTT

Read More

World Health Day: India's healthcare sector reflects 12.59 per cent growth in 2024-25

The hospital market in India, valued at USD 98.98 billion in 2023, is set to continue its upward trajectory, with projections indicating a CAGR of 8.0 per cent from 2024 to 2032. By 2032, the market is estimated to reach value of USD 193.59 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ElbLZT1
via IFTTT

Read More

Sanofi looks for accelerated growth in India; plans fast-tracking of product pipeline

Sanofi, a leading French pharmaceutical company, aims to expand its presence in the Indian market by introducing new drugs, enhancing localization efforts, and collaborating with domestic firms. Managing Director Rodolfo Hrosz highlights the significant growth potential in India and emphasizes the company's focus on addressing the diabetes segment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZpvCd8o
via IFTTT

Read More

India's Ayurveda product market to reach Rs 1.2 lakh crore by FY28: Study

India's Ayurveda market is poised to grow to USD 16.27 billion by FY28, driven by demand for natural remedies, government support, and the sector's potential to position itself in global markets, as highlighted at the CII AYUSH Conclave.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fr5DAdq
via IFTTT

Read More

There can't be shortage of Polio vaccine; Serum Institute can make it: CEO Adar Poonawalla

Pune-based Serum Institute of India (SII) is prepared to increase production of injectable poliomyelitis vaccine (IPV) to fill the gap left by France's Sanofi closing its manufacturing plants in India. SII currently supplies half of the 20 million IPV doses to the government's immunization program and can provide additional doses with a 3-4 month notice. Adar Poonawalla, SII CEO, stated that supplying IPV to the government at current prices is unviable for most companies, but SII continues to do so as a service to the nation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LDpcqXC
via IFTTT

Read More

Apollo Hospitals report finds Indians are getting cancer at lower ages than West

The study, which is the fourth edition of its flagship Health of Nation Report, highlighted the fastest rise in cancer cases and also the average age of incidence has also gotten significantly younger in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4nteOG9
via IFTTT

Read More

Digital database of organ donors on cards for smooth transplants

The register will serve as a single platform with Aadhaar authenticated data for all donors and patients waiting for organ transplant to ensure in-time and transparent organ donation in the country while doing away with the middlemen. India has 0.14 million potential donors who have voluntarily pledged their organs and the government aims to have 10 million prospective donors by the end of 2024 under the Angdaan Mahotsav, which started in July 2023.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IRfmg3D
via IFTTT

Read More

Lupin appoints Dr Ranjana Pathak as chief quality officer

Dr. Ranjana Pathak appointed Lupin's chief quality officer, succeeding Johnny Mikell. With 30 years of experience, she led quality at Cipla, Watson/Actavis, and Endo Pharmaceuticals. Lupin invests in R&D.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/40PQcrC
via IFTTT

Read More

Aster DM completes separation of Gulf business, plans to add 1,700 beds in India in next 3 years

Aster DM Healthcare has finalized the separation of its India and Gulf (GCC) businesses. A consortium led by Fajr Capital acquired a 65% stake in Aster GCC, while the Moopen family retained 35%. In India, the family holds a 41.88% stake. The separation aims to enhance strategic and financial flexibility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/25T4zED
via IFTTT

Read More

General Atlantic buys hospital chain Ujala Cygnus

General Atlantic acquires Ujala Cygnus for Rs1600 crore, with existing investors exiting fully. Ujala Cygnus to enhance infrastructure and care quality. Probal Ghosal and Shantanu Rastogi commend the company's achievements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VMxwpkY
via IFTTT

Read More

Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines production, supply

Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nLyb7Np
via IFTTT

Read More

India all set to make Penicillin G after three decades on PLI push

India stopped producing the two input drugs about three decades ago and since then it has relied on China for their supplies. "As of now, we are largely dependent on China. With the initiative of the production-linked-incentive scheme, companies like Aurobindo are coming up with fermentation-based products like PenG," said Ravi Uday Bhaskar, director general, Pharmaceutical Export Promotion Council (Pharmexcil). "We will be in a better position in the coming few months."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4eMAOZz
via IFTTT

Read More

Mubadala plans big deals in India's healthcare space

Abu Dhabi's Mubadala Investment Company plans to expand in India's healthcare sector, seeking deals in the $200-500 million range. With a focus on pharmaceuticals, outsourced pharma services, and medtech, Mubadala aims to deploy capital meaningfully in India. This move aligns with Mubadala's strategy to generate sustainable financial returns. They have made significant investments globally and are now looking to expand their presence in India's healthcare landscape.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NuwPCDA
via IFTTT

Read More

Alembic Pharma gets tentative USFDA nod for breast cancer drug

The medicine is indicated for the treatment of adult patients with a certain type of advanced or metastatic breast cancer in a combination of drug therapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u6KXnL8
via IFTTT

Read More